Search Results

Transaortic Access May Be a Safe Alternative to Transapical Access for TAVR

September 13, 2016—In the Journal of the American College of Cardiology (JACC): Cardiovascular Interventions, Vinayak Bapat, MD, et al published findings on using transaortic (TAo) access for transcatheter aortic valve replacement (TAVR) in the ROUTE registry (2016;9:1815–1822).  According to the investigators, ROUTE (Registry of the Utilization of the TAo-TAVR Approach Using the Edwards Sapien Valve) was established to assess the safety and effectiveness of the use of TAo access for TAVR procedures.

Early Humanitarian-Use Procedures With Edwards' Fortis Mitral Valve Reviewed

May 20, 2014—Edwards Lifesciences announced that details about the first-in-human experience with the company’s Fortis mitral transcatheter heart valve were presented at the EuroPCR 2014 congress being held in May 20–23, in Paris, France.

Early Outcomes Presented for Medtronic's Intrepid TMVR System

November 1, 2017—Medtronic announced the presentation of data for its self-expanding Intrepid transcatheter mitral valve replacement (TMVR) system in patients with severe, symptomatic mitral valve regurgitation.

Abbott’s Software-Guided TAVI/TAVR System Used in First-in-Human Procedures

December 2, 2024—Abbott recently announced the first patient procedures with its investigational transcatheter aortic valve implantation/replacement (TAVI/TAVR) balloon-expandable system for treating symptomatic severe aortic stenosis.

First Human Implantations Performed With Edwards' Fortis Mitral Transcatheter Valve System

March 6, 2014—Edwards Lifesciences Corporation (Irvine, CA) announced that the first three human implantations of the company’s Fortis mitral transcatheter heart valve were successfully performed via a transapical approach in February and March by the heart team at St.

Abbott’s Epic Plus Tissue Valves Receive FDA Approval for Surgical Mitral and Aortic Valve Replacement

September 22, 2021—Abbott announced FDA approval of the company’s Epic Plus and Epic Plus Supra stented tissue valves to improve therapy options for patients with aortic or mitral valve disease.

Medtronic Begins Early Feasibility Study of Intrepid System to Treat Tricuspid Valve Regurgitation

September 9, 2020—Medtronic announced FDA approval of an early feasibility study of the Intrepid transcatheter tricuspid valve replacement (TTVR) system in patients with severe, symptomatic tricuspid regurgitation.